Skip to content

Search

Cheeky Jackson heads home after 7.5 month nightmare

Michelle Pianta knew deep down something was very wrong with her seven-and-a-half month old son Jackson as she waited at Bunbury Hospital for his blood results.

Drug find could represent big win for our little patients

Dr Rishi Kotecha knows too well the devastation of a leukaemia diagnosis in a child, treating children as a consultant at Princess Margaret Hospital.

Researchers unlock potential new cancer weapon

In an exciting breakthrough for cancer treatment, a new weapon to enable the immune system to combat the disease may have been unlocked.

Funding boost to melanoma research

A The Kids Research Institute Australia researcher will investigate new ways to harness the body’s own immune system to fight melanoma, thanks to Cancer Council WA funding.

Global war on brain cancer

Dr Nick Gottardo and Dr Raelene Endersby from The Kids Research Institute Australia are the driving force behind an innovative, global action group on child brain cancer.

Editorial: Bench to bedside: translating pre-clinical research into clinical trials for childhood brain tumors

Nick Raelene Gottardo Endersby MBChB FRACP PhD BSc (Hons) PhD Co-Head, Brain Tumour Research team; Head of Oncology and Haematology, Perth Children’s

Disruption of cotranscriptional splicing suggests that RBM39 is a therapeutic target in acute lymphoblastic leukemia

There are few options for patients with relapse/refractory B-cell acute lymphoblastic leukemia, thus this is a major area of unmet medical need. Here, we reveal that inclusion of a poison exon in RBM39, which could be induced both by CDK9 or CDK9 independent CMGC (cyclin-dependent kinases, mitogen-activated protein kinases, glycogen synthase kinases, CDC-like kinases) kinase inhibition, is recognized by the nonsense-mediated mRNA decay pathway for degradation.

Childhood leukaemia in Down's syndrome primed by blood-cell bias

An in-depth investigation of gene regulation and cell populations at sites of fetal blood-cell production provides clues as to why children with Down’s syndrome are predisposed to developing leukaemia.

Transcriptional rewiring in CD8+ T cells: implications for CAR-T cell therapy against solid tumours

T cells engineered to express chimeric-antigen receptors (CAR-T cells) can effectively control relapsed and refractory haematological malignancies in the clinic. However, the successes of CAR-T cell therapy have not been recapitulated in solid tumours due to a range of barriers such as immunosuppression, poor infiltration, and tumour heterogeneity.

Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade

W. Joost Ben Lizeth Rachael Tao Omar Lesterhuis Wylie Orozco Morales Zemek Wang Elaskalani BSc PhD BSc, MSc, PhD BSc (Hons), PhD PhD BSc, MSc, PhD